Paid

 Studies show that patients with type 2 diabetes are more likely to exhibit reduced cognitive function after a stroke.  

Research into a new insulin analog with similar safety and efficacy as current long-acting insulins may help overcome clinical inertia. 

A new study shows that metformin may have a previously unknown mechanism of action that could lead to new and improved diabetes medications. 

Danish study makes strong recommendations for diabetes pharmacotherapy beyond metformin. 

Imeglimin, a new, first-in-class blood-glucose-lowering agent, proves to be safe and efficient as monotherapy and adjunctive therapy to lower A1C in patients with type 2 diabetes. 

Study of BMI and ESRD suggests obesity may provide a health benefit when it comes to end-stage renal disease.

The new HbA1c variability score (HVS) allows HbA1c variability to be more easily and consistently studied.

 Why are younger patients with diabetes not seeing the same improvements as those over 45? 

Certain inflammatory biomarkers may help lead to improvements in the treatment of diabetes. 

Arterial stiffness is a complication of cardiovascular disease; does skipping meals contribute to this condition in patients with type 2 diabetes mellitus?